Jb Chemicals & Pharmaceuticals Limited (JBCHEPHARM)
ISIN: - Industry: Drug Manufacturers—Specialty & Generic Sector: Healthcare Website
2018.2
2.9(0.14%)

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets various pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients in India and internationally. Its principal products include Cilnidipine, Ranitidine, and Metronidazole. The company also provides contract manufacturing services for tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, it offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners. Further, the company provides its services in gastroenterology, hypertension, diabetes, dermatology, nephrology, wound care, anti-infectives, and pharmacovigilance therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is based in Mumbai, India.

Pricing Updates

TODAY'S HIGH

2033.75

TODAY'S LOW

2010.55

52 WEEK HIGH

2150

52 WEEK LOW

1342.2

Major Holders

% of Shares Held by
All Insider

54.32%

% of Shares Held by
Institutions

23.52%

% of Float Held by
Institutions

51.49%

Number of Institutions
Holding Shares

62

Company Overview

MARKET CAP

15625.95 Cr.

ETERPRISE VALUE

15763.24 Cr.

NO. OF SHARES

7.73 Cr.

BOOK VALUE

299.385

DIV. YIELD

8%

DEBT

374.65 Cr.

GROSS PROFIT

1558.79 Cr.

CASH

196.81 Cr.

REVENUE

2819.49 Cr.

REVENUE/SHARE

364.814

OHLC Chart 1y 2y 5y 10y

Price Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Volumes Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Cashflows

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Investments700.20 Cr.-224.06 Cr.91.25 Cr.10.37 Cr.
Change To Liabilities52.83 Cr.46.47 Cr.52.10 Cr.-28.57 Cr.
Total cashflows from Investing Activities2.31 Cr.-230.67 Cr.23.92 Cr.-27.66 Cr.
Net Borrowings-8.36 Cr.-7.83 Cr.-2.36 Cr.-5 Lakhs
Total Cash from Financing Activities-138.38 Cr.-87.42 Cr.-306.05 Cr.-155.73 Cr.
Other Liabilities00021 Cr.
Total Assets0000
Net Income385.35 Cr.447.96 Cr.272.04 Cr.193.46 Cr.
Change in Cash34.07 Cr.-3.27 Cr.-6.38 Cr.10.89 Cr.
Effect of Exchange Rate10 k3.55 Lakhs-1.29 Lakhs-2.31 Lakhs
Total Cash from Operating Activities170.13 Cr.314.78 Cr.275.74 Cr.194.32 Cr.
Depreciation72.65 Cr.68.32 Cr.65.99 Cr.54.87 Cr.
Other Cashflows from Investing Activities1.12 Cr.1.27 Cr.3.17 Cr.3.75 Cr.
Dividends Paid-127.56 Cr.-73.24 Cr.-141 Cr.-20.79 Cr.
Change to Inventory-62.51 Cr.-70.08 Cr.-30.91 Cr.-30.02 Cr.
Change to Account Receivables-292.83 Cr.-70.59 Cr.-11.49 Cr.-13.87 Cr.
Other Cashflows from Financing Activities-2.45 Cr.-6.34 Cr.-1.86 Cr.-3.86 Cr.
Change to Net Income14.63 Cr.-107.63 Cr.-72.32 Cr.-3.31 Cr.
Capital Expenditures-62.87 Cr.-47.77 Cr.-72.96 Cr.-49.12 Cr.

Financials

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Research DevelopmentNoneNoneNoneNone
Effect of Accounting ChargesNoneNoneNoneNone
Income Before Tax504.90 Cr.596.88 Cr.348.89 Cr.286.99 Cr.
Minority Interest4.48 Cr.3.70 Cr.2.50 Cr.2.80 Cr.
Net Income470.79 Cr.487.31 Cr.318.21 Cr.258.25 Cr.
Selling General Administrative439.24 Cr.425.77 Cr.406.83 Cr.382.03 Cr.
Gross Profit1581.30 Cr.1319.80 Cr.1122.22 Cr.1023.93 Cr.
Ebit470.79 Cr.487.31 Cr.318.21 Cr.258.25 Cr.
Operating Income470.79 Cr.487.31 Cr.318.21 Cr.258.25 Cr.
Other Operating Expenses598.61 Cr.338.05 Cr.330.84 Cr.328.13 Cr.
Interest Expense-5.12 Cr.-6.74 Cr.-2.91 Cr.-3.41 Cr.
Extraordinary ItemsNoneNoneNoneNone
Non RecurringNoneNoneNoneNone
Other ItemsNoneNoneNoneNone
Income Tax Expense118.86 Cr.148.36 Cr.76.50 Cr.93.02 Cr.
Total Revenue2424.24 Cr.2042.52 Cr.1774.72 Cr.1643.20 Cr.
Total Operating Expenses1953.44 Cr.1555.21 Cr.1456.51 Cr.1384.94 Cr.
Cost of Revenue842.93 Cr.722.71 Cr.652.50 Cr.619.26 Cr.
Total Other Income Expense Net34.10 Cr.109.57 Cr.30.67 Cr.28.73 Cr.
Discontinued OperationsNoneNoneNoneNone
Net Income from Continuous Ops.386.03 Cr.448.52 Cr.272.39 Cr.193.96 Cr.
Net Income Applicable to Common Shares385.35 Cr.447.96 Cr.272.04 Cr.193.46 Cr.

Balance Sheet

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Intangible Assets671.39 Cr.32.10 Cr.30.09 Cr.23.37 Cr.
Capital Surplus050.76 Cr.50.76 Cr.50.76 Cr.
Total Liabilities468.78 Cr.424.68 Cr.382.57 Cr.309.02 Cr.
Stock Holder Equity2134.12 Cr.1809.72 Cr.1435.48 Cr.1480.12 Cr.
Minority Interest4.48 Cr.3.70 Cr.2.50 Cr.2.80 Cr.
Other Liabilities125.29 Cr.102.68 Cr.103.72 Cr.97.03 Cr.
Total Assets2607.40 Cr.2238.11 Cr.1820.56 Cr.1791.94 Cr.
Common Stock15.45 Cr.15.45 Cr.15.45 Cr.16.04 Cr.
Retained Earnings01735.41 Cr.1373.37 Cr.1413.87 Cr.
Other Liabilities64.45 Cr.74.27 Cr.68.07 Cr.64.83 Cr.
Good Will57.45 Cr.57.45 Cr.53.14 Cr.53.14 Cr.
Treasury Stock2118.66 Cr.8.08 Cr.-4.10 Cr.-56.98 Lakhs
Other Assets19.33 Cr.13.38 Cr.10.52 Cr.8.89 Cr.
Cash58.52 Cr.28.68 Cr.29 Cr.35.39 Cr.
Current Liabilities383.71 Cr.345.27 Cr.313.26 Cr.244.18 Cr.
Long Term Asset Charges6.43 Cr.6.94 Cr.6.57 Cr.0
Short Long Term Debt0000
Other Stockholder Equity2118.66 Cr.8.08 Cr.-4.10 Cr.-56.98 Lakhs
Property Plant Equipment566.81 Cr.569.65 Cr.584.19 Cr.559.50 Cr.
Total Cur. Assets1274.85 Cr.1552.60 Cr.1073.15 Cr.1051.15 Cr.
Long Term Investments17.54 Cr.12.90 Cr.69.45 Cr.95.87 Cr.
Net Tangible Assets1405.26 Cr.1720.16 Cr.1352.25 Cr.1403.60 Cr.
Short Term Investments0002.99 Cr.
Net Receivables556.99 Cr.399.24 Cr.361.35 Cr.324.83 Cr.
Long Term Debt0000
Inventory409.96 Cr.347.44 Cr.274.66 Cr.243.75 Cr.
Accounts Payable224.47 Cr.186.92 Cr.167.96 Cr.117.37 Cr.

New Offers


Upstox offer
Upstox

Open a demat account through us and get the account opening charges waived off

open paperless account